Other Rx complications or No further Rx 
medical conditions which 
substantially risk to patient 
Symptomatic tumor No further Rx 
progression requiring other 
Rx e.g. RT or chemo 
9.0 Ancillary Treatment 
Symptomatic care may be given as required with medications such as antiemetics 
and analgesics. However, administration of corticosteroids will require that the 
patient be removed from study. 
10.0 Toxicity Monitoring and Adverse Reaction Reporting 
Patients will be monitored and questioned at every visit (see Schedule of 
Events)regarding the occurrence and nature of any adverse experiences. An event 
any change in the physiological or psychological state other than the primary 
condition that qualifies the patient for this study. 
The Investigator must report to Mr. Steven Kradjian (ph 619-453-9777, available 24 
hours.) upon occurrence of any life-threatening events (Grade IV) that may be 
attributable to administration of the study drug, all fatal events, or the first 
occurrence of any previously unknown clinical event (regardless of Grade). A 
written report is to follow within 3 working days to: 
Steven A. Kradjian, Director 
Regulatory Affairs, Vical Inc. 
9373 Towne Centre Dr., Suite 100 
San Diego, CA 92121 
Patients will be taken off study immediately if: 
Unacceptable toxicity (Grade III or IV) develops and is not easily corrected (refer 
to WHO toxicity sheet). 
Development of Progressive Disease (see definition) requiring the institution of 
alternative treatments such as radiation, surgery or other drug therapy. If the 
Investigator believes that the patient's best interest equires a change of therapy. 
At the patient's request. 
10.1 Toxicities to be graded at each evaluation and pre-treatment 
symptoms /conditions to be evaluated at baseline per WHO Criteria: 
Toxicity / symptoms Baseline 
Fatigue X 
Weight loss / anorexia X 
Nausea X 
Vomiting X 
Hemorrhage 
Infection 
Each 
Evaluation 
X 
X 
X 
X 
X 
X 
Recombinant DNA Research, Volume 19 
[219] 
